SCHEMBL1711958

SCHEMBL1711958

COc1cnc2cccc(C(CO)CNC(=O)OC(C)(C)C)c2n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 10/20 0.39
MTNR1A P48039 9/20 0.39
HTR2C P28335 6/20 0.39
KDM4E B2RXH2 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
BCHE P06276 1/20 0.36
GFER P55789 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PCSK9 Q8NBP7 1/20 0.35
BRD4 O60885 1/20 0.34
SYK P43405 1/20 0.34
NQO2 P16083 1/20 0.34
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711909 0.88 KDM4E (0.38) MTNR1BMTNR1AKDM4ETDP1BCHE
SCHEMBL1712711 0.88 KDM4E (0.38) MTNR1BMTNR1AKDM4ETDP1BCHE
SCHEMBL2286483 0.86 MTNR1B (0.39) MTNR1BMTNR1AKDM4ETDP1BCHE
SCHEMBL1723633 0.85 KDM4E (0.38) MTNR1BMTNR1AHTR2CKDM4ETDP1
SCHEMBL1723635 0.85 KDM4E (0.38) MTNR1BMTNR1AHTR2CKDM4ETDP1
SCHEMBL1723632 0.85 KDM4E (0.38) MTNR1BMTNR1AHTR2CKDM4ETDP1
SCHEMBL1712708 0.84 KDM4E (0.39) MTNR1BMTNR1AKDM4ETDP1MEN1
SCHEMBL1711908 0.84 KDM4E (0.39) MTNR1BMTNR1AKDM4ETDP1MEN1
SCHEMBL3888157 0.80 ACACB (0.34) MTNR1BMTNR1AKDM4ETDP1BCHE
SCHEMBL3818896 0.80 CPB2 (0.34) MTNR1BMTNR1AKDM4ETDP1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822114-B2 Tricyclic oxazolidinone antibiotic compounds IDORSIA PHARMACEUTICALS LTD (CH) 2017-11-21 US disclosed
US-20160237088-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS IDORSIA PHARMACEUTICALS LTD (CH) 2016-08-18 US disclosed
US-9346804-B2 Tricyclic oxazolidinone antibiotic compounds ACTELION PHARMACEUTICALS LTD. (CH) 2016-05-24 US disclosed
EP-2344495-B1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2014-12-31 EP disclosed
US-20140142093-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2014-05-22 US disclosed
US-8618092-B2 Tricyclic oxazolidinone antibiotic compounds ACTELION PHARMACEUTICALS LTD. (CH) 2013-12-31 US disclosed
US-20110195961-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-11 US disclosed
EP-2344495-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2011-07-20 EP disclosed
WO-2010041194-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195961-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS HRH3, OXA1L, HRH1 MTNR1B 670/4885MTNR1A 987/4885HTR2C 2460/4885
US-20160237088-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS H1-3, HRH3, HRH4 MTNR1B 860/4885MTNR1A 1089/4885HTR2C 1149/4885
US-20140142093-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS OXA1L, H1-3, NGLY1 MTNR1B 897/4885MTNR1A 1119/4885HTR2C 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.